Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC

Nutra Pharma has introduced Nyloxin OTC, an over-the-counter (OTC) drug for the treatment of chronic pain. Nyloxin OTC will be marketed and sold internationally alongside the company’s prescription pain reliever, Nyloxin Rx.

Paul Reid, CEO of ReceptoPharm, said: “Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States.

“By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC.”

Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.

Rik Deitsch, chairman and CEO of Nutra Pharma, said: “The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines. With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market.”

Nyloxin OTC, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.